that binding of the peptide to MHC is similar to that of the canonical peptide OVA8 (SIINFEKL).
Introduction
Immunization with peptides derived from tumour antigens was successful in experimental mouse models with the induction of cytotoxic T lymphocytes (CTL) and tumour protection. 1 The efficacy of the immunization depends on the ability of peptides to induce and activate high-avidity CTL. High-affinity peptides from non-self antigens that bind to major histocompatibility complex (MHC) class I molecules usually induce such high-avidity CTLs. However, if the peptide is derived from a tumour antigen, vaccination may not be effective. MUC1, like most other tumour antigens, is expressed in normal tissues and overexpressed on cancer cells [termed tumour-associated antigens (TAA)]. Since most tumour antigens are self antigens, their specific CTL repertoire would most likely be deleted, as demonstrated for p53, [2] [3] [4] [5] [6] leading to tolerance. This tolerance is particularly associated with the high-affinity MHC-associated immunodominant epitopes, but not with low-affinity epitopes. 7 Thus, for tumour immunotherapy, it is conceivable that the best candidate peptides for immunization are lowaffinity peptides. [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] However, peptide affinity and stability of the peptide-MHC complex have been shown Eliada Lazoura, 1 Jodie Lodding,
Summary
Designing peptide-based vaccines for therapeutic applications in cancer immunotherapy requires detailed knowledge of the interactions between the antigenic peptide and major histocompatibility complex (MHC) in addition to that between the peptide-MHC complex and the T-cell receptor. Past efforts to immunize with high-affinity tumour-associated antigenic peptides have not been very immunogenic, which may be attributed to the lack of T cells to these peptides, having been deleted during thymic development. For this reason, low-to-medium affinity non-canonical peptides represent more suitable candidates. However, in addition to the difficulty in identifying such antigens, peptide binding to MHC, and hence its ability to induce a strong immune response, is limited. Therefore, to enhance binding to MHC and improve immune responses, anchor modifications of non-canonical tumour-associated peptides would be advantageous. In this study, the non-canonical tumour-associated peptide from MUC1, MUC1-8 (SAPDTRPA), was modified at the MHC anchor residues to SAPDFRPL (MUC1- 
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to correlate with overall immunogenicity. 19, 20 Thus, a major problem in using low-affinity peptide epitopes for immunotherapy is the difficulty of their identification. Because such low-affinity peptides cannot be detected by elution studies and prediction algorithms, the only effective method for their identification is by systematic binding studies and recognition of peptide-MHC (pMHC) complexes by T-cell receptor (TCR). Therefore, it would be desirable to enhance the immunogenicity of low-affinity MHC-binding peptides by mutations of the peptide anchor side chains to increase their affinity.
The MHC class I molecule comprises a polymorphic glycosylated heavy chain (extracellular a1, a2 and a3 domains and short hydrophilic cytoplasmic tail) which is non-covalently associated with b 2 -microglobulin. The a1 and a2 domains combine to form the peptide-binding groove of MHC. Understanding the mode of peptide binding to MHC class I molecules, with subsequent binding of the pMHC complex to the TCR, is a prerequisite to effective peptide vaccine design. Presently, canonical consensus sequences dominate the selection process. 19, [21] [22] [23] Numerous X-ray crystallographic studies have shown how a number of different high-affinity eight-or ninemer peptides bind to the mouse MHC class I molecule, H-2K b , and despite differences in the primary structure of these peptides, they all bound with similar conformations. [24] [25] [26] It is well documented that peptides that bind to H-2K b require the amino acids, F/Y at position 5 (P5) and M/V/L at P8 for eight-mer peptides; P5 generally binds in the 'C' pocket and P8 binds in the 'F' pocket. However, it is now recognized that peptides with noncanonical anchors can bind to H-2K b and still induce T-cell responses. 8, 9, 14, 27, 28 Indeed, the X-ray crystal structure of the low-affinity non-canonical anchor motifcontaining peptide, MUC1-8 (SAPDTRPA), derived from mucin 1 (MUC1), 14 contained the small polar amino acid Thr at P5 and small non-polar Ala at P8 and bound in the C and F pockets, respectively.
14 The backbone structure of the low-affinity peptide, MUC1-8, bound similarly to high-affinity peptides, except, the C and F pockets were not completely filled, resulting in large cavities. We recently demonstrated that modifying the central Thr amino acid to Thr-GalNAc increased the affinity of the peptide and the GalNAc residue enabled high-affinity binding and generated high avidity T-cell responses. 16 Herein, mutations to the MUC1-8 peptide were introduced at either or both, the central (P5) or C-terminal (P8) anchor residues, to increase the binding affinity to H-2K b . Specifically, MUC1-8-5F (substituting Thr-P5 to Phe), MUC1-8-8L (substituting the Ala-P8 to Leu) and MUC1-8-5F8L (substitutions of Thr-P5 to Phe and Ala P8 to Leu) anchor-modified peptides were tested. In this study, we determined the X-ray crystal structure of MUC1-8-5F8L peptide in complex with H-2K b at a resolution of 2Á7 Å . The structure was compared to that of the non-canonical parent peptide MUC1-8 and the canonical OVA8 peptide (SIINFEKL). In addition, by molecular modelling we predicted the structures of MUC1-8-5F and MUC1-8-8L. MUC1-8-5F8L peptide displayed the highest affinity for H-2K b and was more immunogenic in MUC1 · HLA-A2 transgenic mice; MUC1-8 in these mice was weakly immunogenic.
Materials and methods

Peptides
Peptides, SAPDTRPA (MUC1-8) the anchor modified analogues SAPDFRPA (MUC1-8-5F), SAPDTRPL (MUC1-8-8L) and SAPDFRPL (MUC1-8-5F8L) were synthesized. The high-affinity binding peptides, SIINFEKL -chicken ovalbumin 257)264 (OVA8), FAPGNYPAL -Sendai virus NP 324)332 (SEV9) and RGYVYQGL -vesicular stomatitis virus NP 52)59 (VSV8) were used in this study to compare to MUC1-8 anchor-modified peptides. All peptides were synthesized by Chiron Mimotopes (Clayton, VIC, Australia); the purity was > 95% and molecular weights were confirmed by electrospray mass spectroscopy.
Production of soluble H-2K b
The soluble extracellular domains of H-2K b (heavy-chain residues 1-274 with C-terminal His-tag and b 2 -microglobulin residues 1-99) were expressed in Drosophila melanogaster cells, under the control of a metallothione promoter as previously described. 25, [29] [30] [31] Briefly, D. melanogaster cells were expanded to a large scale (up to 6 l) in serum free Insect Xpress Ò media (Cambrex, East Rutherford, NJ) and CuSO 4 (625 lM final concentration) was added 3-5 days before harvesting to induce expression of H-2K b . The supernatant was concentrated using a CENTRAMATE tangential flow concentrator (PALL, East Hills, NY) using a 10 000 MWCO membrane (PALL) and then loaded onto a nickel-nitrilotriacetic acid (Ni-NTA) column and eluted using 10-250 mM imidazole buffer gradient, pH 7Á5. Further purification was achieved using a Mono-Q column (GE Healthcare, Piscaloway, NJ; elution using 25-500 mM NaCl gradient, in a Tris-HCl buffer, pH 8Á0) and the final sample was dialysed overnight against double-distilled water. This was further concentrated using a Nanosep 10 000 MWCO concentrator (PALL) to achieve final concentrations of 10-15 mg/ml, which were checked using the NanoDrop spectrophotometer (NanoDrop Technologies, Wilmington, DE).
Affinity measurements
Affinity measurements for binding of peptides to soluble H-2K b molecules were performed as previously described. 30, 32 All affinity measurements were repeated at least two or three times.
Peptide stabilization assay using RMA-S cells MHC class I molecules in the murine cell line RMA-S (C57BL/6 TAP2-deficient cells) can be used to measure the direct binding of peptides to class I molecules in vitro. RMA-S cells (5 · 10 5 cells) were incubated with peptides (10 )4 to 10
M) at 26°for 3 hr then transferred to 37°f or 30 min. After washing with 0Á5% bovine serum albumin/phosphate-buffered saline (2 ml), anti-H-2K b (HB-158) immunoglobulin G2a as supernatant (1/50 dilution, 100 ll) was added to RMA-S peptide-loaded cells and incubated for 45 min at 4°. The cells were washed once again and 100 ll (1=500 dilution) of fluorescein isothiocyanate-conjugated sheep (Fab 0 ) 2 anti-mouse immunoglobulin was added and incubated for 45 min at 4°; after further washing, cells were analysed by FACScan.
Mice, generation of dendritic cells (DC) and immunizations
/HLA-A2) transgenic 6-to 8-week-old mice were used in the experiments. Bone marrow cells from C57BL/6 or MUC1 · HLA-A2 female mice were cultured at 1 · 10 6 cells/ml in tissue culture media, supplemented with 10 ng/ml granulocyte-macrophage colony-stimulating factor/interleukin-4. At day 6, cells were washed, re-suspended in the same culture medium and 20 lg/ml peptides were loaded on DCs for 3 hr. Pulsed DC were washed and 100 ll (1 · 10 6 )2 · 10 6 cells) was injected intradermally in female mice into the base of tail. After 14 days mice were boosted and 16 days later splenocytes were assessed by ELISpot. All animal studies were approved by the Austin Health ethics committee.
ELISpot assay
To assess peptide specific interferon-c (IFN-c) production by CD8 + T cells to each peptide, splenocytes from immunized mice were used in IFN-c ELISpot assays. Spleen cells were incubated with 10 )5 to 10
M of each MUC1 peptide, irrelevant peptide (OVA8, SIINFEKL) or internal positive control concanavalin A for 18 hr at 37°, 8% CO 2 on nitrocellulose plates (precoated with an antimurine IFN-c monoclonal antibody). Plates were developed as previously described. [33] [34] [35] Preparation and crystallization of the
The soluble extracellular domains of H-2K b (heavy chain residues 1-274 and b 2 -microglobulin residues 1-99) were expressed in Drosophila melanogaster cells, as previously described. 25, [29] [30] [31] Large crystals of the H-2K b -MUC1-8-5F8L complex (> 10 mg/ml) grew in 1Á8-2Á0 M NaH 2 PO 4 / K 2 HPO 4 with 1-2% (v/v) 2-methyl-2,4-pentanediol (MPD), pH 6Á6-7Á4, at 18°with fivefold molar excess of MUC1-8-5F8L peptide. H-2K b and peptide were both in double-distilled water (preincubated overnight at 4°b efore crystal set up), and crystals were set up using the sitting drop vapour diffusion method, with 0Á5 ll MHCpeptide mixture applied to the platform immediately followed by the addition of 0Á5 ll of mother liquor. One millilitre of mother liquor was added to each well of a 24-well Cryschem plate (Hampton Research, Aliso Viejo, CA). Crystals appeared within 5 days and grew to dimensions of 0Á2 · 0Á2 · 0Á1 mm within 2 weeks.
Data collection and structure determination
Before data collection, crystals were harvested in a NaH 2 PO 4 /K 2 HPO 4 solution, 0Á2 M lower than that in which the crystals were grown, 1-2% MPD, pH 6Á6-7Á4 and 25% (v/v) glycerol as cryoprotectant. Crystals were cryocooled to ) 170°in a nitrogen gas stream. X-ray diffraction data were collected using a MicroMax007 Rigaku X-ray generator (Rigaku, Tokyo, Japan) operated at 40 kV and 20 mA. X-rays were focused to 0Á3-mm diameter using Osmic Blue confocal optics and diffraction images (Du ¼ 0Á5°) were captured on an R-Axis IV ++ detector at a crystal-to-detector distance of 200 mm. Diffraction data were processed using the HKL program suite version 1.96.6.
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Relevant data-processing statistics are presented in Table 1 .
The H-2K b -MUC1-8-5F8L crystals belong to the orthorhombic P2 1 2 1 2 space group, as do the MUC1-8, OVA8, VSV8, SEV9 and YEA9-H-2K b complexes. 13, 14, 25, 26 The structure was determined by phasing the data using the co-ordinates of the high resolution (1Á6 Å ) H-2K b -MUC1-8 structure (PDB 1G7Q 14 ) using the CNS program. The MUC1-8 peptide was initially removed and the MUC1-8-5F8L peptide was built into the |F o | -|F c | electron density using the program TURBO-FRODO version 5Á5 (BioGraphics, Marseille, France). 37 Cross-validated crystallographic refinements against maximum likelihood targets were carried out with the CNS program suite, version 0Á9. 38 Between cycles of crystallographic refinement, the model was fitted to 2|F o | ) |F c | and |F o | ) |F c | maps on a Silicon Graphics workstation, using the program TURBO-FRODO. 37 The carbohydrate moieties (NAG and FUC), PO 4 3-ions and solvent (MPD and water) were added to the model when the crystallographic R-factor (R work ) dropped below 0Á25. A bulk solvent correction and anisotropic overall B-factor refinements were applied during the last cycles of the structure refinement. Table 2 summarizes the last stage of refinement and the quality of the model as assessed by PROCHECK.
39 Analysis of the final model with PROCHECK 39 showed 89Á3% of the residues are in the most favoured regions of the Ramachandran plot, with none in the disallowed regions. The electron density for all residues was well-defined, except for the MHC polypeptide turn side chain regions. Figures were prepared using TURBO-FRODO 5Á5 and DS MODELING 1Á1 (Accelrys Inc., San Diego, CA).
Protein Data Bank accession codes
The atomic co-ordinates and structure factors for the H-2K b -MUC1-8-5F8L complex have been deposited in the RCSB Protein Data Bank with accession code 2FO4.
Molecular modelling
Models of the MUC1-8 peptide analogues (MUC1-8-5F and MUC1-8-8L) were based on the MUC1-8-5F8L crystal structure of the a-chain of the mouse MHC class I molecule H-2K b complexed to MUC1-8-5F8L (described herein). Molecular modelling was performed with the DS MODELING 1Á1 software (Accelrys) using the CHARMm forcefield to optimize the molecular geometry. Before the molecular dynamics simulation, structures were relaxed using a steepest descent gradient algorithm until the root mean square deviation (RMSD) was less than 0Á1 kcal/ mol, then followed by the Adopted Basis-set NewtonRaphson algorithm until the RMSD was less than 0Á01 kcal/mol. A distance dependent dielectric was used to simulate aqueous solvent conditions. Peptide molecules and all atoms within a 20-Å radius of the peptide were subsequently heated to room temperature (300 K) in 1000 steps and equilibrated at this temperature for a further 1000 steps before commencing the molecular dynamics run for 200 ps, storing the structure every 100 steps.
The final conformation was selected for all further analysis. The RMSD between the main-chain Ca atoms was calculated for all residues between MUC1-8, OVA8, MUC1-8-5F8L and the anchor-modified analogues (MUC1-8-5F and MUC1-8-8L) as a measure of variation in peptide conformation. All satisfied H-bonds and salt bridges between peptide and H-2K b molecule were identified.
Results
Affinity measurements of MUC1-8 peptide mutants with soluble H-2K b
As the MUC1-8 peptide did not contain any preferred anchor residues at P2, P5 and P8, it was found to bind with low affinity, but induced CTLs in C57BL/6 mice. 14 The affinity of MUC1-8 was measured in an inhibition assay to be 4Á3 · 10
M at 23°(100-300-fold lower than OVA8, or other high-affinity peptides VSV8 and SEV9; Table 2 ).
14 Mutation of Thr-P5 to Phe-P5 (MUC1-8-5F) increased peptide affinity by at least sevenfold at 23°and 37°, and mutation of Ala-P8 to Leu-P8 (MUC1-8-8L) increased affinity by at least threefold at 23°a nd 37°, whilst the double mutant of Thr-P5/Ala-P8 to Phe-P5/Leu-P8 (MUC1-8-5F8L) increased the affinity of the peptide significantly more than the single mutants, by 14-fold at 23°, and provided higher thermal stabilization at 37°( M (Fig. 1) .
Generation of T cells in vivo
The ex vivo 18 hr ELISpot assay does not require cell expansion because it detects specifically activated memory effector cells (both CD4 and CD8 cytokine-producing terminal effectors). The sensitivity of the assay is higher than limiting dilution analysis, FACscan analysis or enzymelinked immunosorbent assay, and can reliably detect the precursor frequencies of antigen-specific effectors of 1 in every 500 000 cells. 14, 16, [40] [41] [42] [43] [44] It is therefore an appropriate method to detect antigen-specific cells at low precursor frequencies as demonstrated previously in malaria models [40] [41] [42] [43] [44] and thus, we did not do CTL assays. The ability of MUC1-8, MUC1-8-5F, MUC1-8-8L, MUC1-8-5F8L peptides to induce T-cell responses in C57BL/6 mice was measured using IFN-c by ELISpot analysis after recognition of MUC1-8, MUC1-8-5F, MUC1-8-8L and MUC1-8-5F8L peptides at varying concentrations ( (Fig. 2a.i) . T cells from mice immunized with DC-MUC1-8-5F or MUC1-8-5F8L generated IFN-c-secreting T cells which recognized all peptides in the range 10 )10 to 10 )5
M; however, the number of spot-forming units (SFU)/500 000 was higher in mice immunized with MUC1-8-5F8L (Fig. 2a.ii,iii) . Mice immunized with MUC1-8-8L generated T cells that recognized all other peptides at 10 )9 to 10 )5 M (Fig. 2a.iv) . Thus, the induction of T cells correlated with the affinity of the peptide, i.e. in increasing strength is, MUC1-8-5F8L > MUC1-8-5F > MUC1-8-8L > MUC1-8.
As it is clear that MUC1-8 is immunogenic in C57BL/ 6 mice it is not immunogenic in MUC1 · HLA-A2 transgenic mice (Fig. 2b.i) . However, mutations to the MUC1-8 peptide to result in MUC1-8-5F, MUC1-8-5F8L and MUC1-8-8L increased the magnitude of T-cell responses in MUC1 · HLA-A2 transgenic mice (where MUC1-8 is self) (Fig. 2b) ; MUC1-8-5F and MUC1-8-8L recognized all peptides 10-fold higher than MUC1-8 ( Fig. 2b.i ,ii,iv) and mice immunized with the double mutant peptide analogue MUC1-8-5F8L generated even higher affinity T cells which recognized all peptides (Fig. 2b.iii) . Furthermore, immunization of MUC1-8 peptide yielded a precursor frequency of 200 SFU/ 500 000 cells, i.e. 1/2500; immunization of MUC1-8-5F8L resulted in a precursor frequency of 400 SFU/ 500 000 cells, i.e. 1/1250. A twofold increase in precursor frequency can have dramatic effects on the protective efficacy of peptides in vivo and the recognition of tumour cells by CTL. We have demonstrated this for a range of MUC1 antigen formulations, where the precursor frequency correlated with tumour protection and CTL induction, and even a twofold increase gave dramatic effects. 45 In addition, our study and other studies of liver-stage malaria have shown a fourfold increase in protective efficacy of CD8 T cells upon a twofold increase in precursor frequency (from 1/8000 to 1/ 4000). 42 Importantly, the difference in these frequency values is statistically significant, indicating that MUC1-8-5F8L binds with higher affinity, providing quantitative functional data to corroborate the binding assay data demonstrated in Fig. 1 and Table 2 . It is clear that, mutations to the native MUC1-8 peptide could overcome tolerance and result in generation of higher affinity T cells. Binding of MUC1-8-5F8L mutant peptide with H-2K b -X-ray crystal structure
The crystal structure of H-2K b -MUC1-8-5F8L at 2Á7 Å resolution was determined by molecular replacement and refined to a final R work of 19Á3% and an R free of 24Á7% (Table 1) . The final atomic co-ordinates consisted of H-2K b heavy chain (residues 1-274), b 2 -microglobulin (residues 1-99), four carbohydrate moieties (NAG at Asn 86 and NAG and FUC at Asn 176 of the heavy chain) and all peptide residues, P1-P8 (MUC1-8-5F8L). Additionally, two phosphate (PO 4 3-) and four MPD molecules were located. Electron density for the bound peptide was continuous and well resolved (Fig. 3a) .
Superposition of MUC1-8-5F8L, MUC1-8 and OVA8 showed similar overlays when viewed from the side (Fig. 3b,c) . The RMSD between MUC1-8 and MUC1-8-5F8L was very low (0Á19 Å , Table 3 ), while that of OVA8 and MUC1-8-5F8L was considerably higher (0Á57 Å , Table 3 ), but comparable with that between MUC1-8 and OVA8 (RMSD 0Á51 Å ; Fig. 3d ).
Interactions of MUC1-8-5F8L peptide with H-2K
b -X-ray crystal structure
High-affinity interactions are consistent with the formation of a highly conserved hydrogen bond network between the side chains of the MHC and the peptide backbone, mainly around the N and C termini, and the optimal fit of peptide side chains into the MHC pockets. Intermolecular H-bonds between peptide residues and MHC are summarized in Table 4 and Fig. 4 . The number of water molecules located in the near vicinity of the peptide within the MHC groove varied between the crystal structures of MUC1-8-5F8L, MUC1-8 and OVA8. Fewer water molecules were found in the MUC1-8-5F8L crystal structure (six water molecules; Fig. 5a ) than in the MUC1-8 crystal structure (10 water molecules; Fig. 5b ), or in OVA8 (seven water molecules; Fig. 5b b groove is predominantly attributed to the contribution of H-bonding and salt bridge formation. In addition, the involvement of water molecules, which assist with the binding of peptide residues to relevant residues within the H-2K b pockets, namely C and F, is also a major contributing factor. Both C and F pockets of the H-2K b -MUC1-8-5F8L crystal are occupied by the P5 and P8 side chains, similar to that observed for OVA8. The modification of the small P5 and P8 anchor residues of MUC1-8 to Phe and Leu, respectively, contributed to the strong binding of the MUC1-8-5F8L peptide to H-2K b . In contrast, the weak binding of MUC1-8 to H-2K b can be attributed to the lack of appropriate anchors at these positions to fill these pockets. As a result, the binding of peptide to MHC is via indirect H-bonding with water molecules in the vicinity of pockets C and F.
Interactions of MUC1-8 peptide analogues with H-2K
b -molecular modelling
The crystal structure of MUC1-8-5F8L was used to model the MUC1-8-5F and MUC1-8-8L peptide analogues. These resulting models were compared with the MUC1-8-5F8L crystal structure (described herein) as well as the parent non-canonical peptide MUC1-8 (1G7Q) and the canonical peptide OVA8 (1VAC) crystal structures. Comparisons were also made between MUC1-8-5F8L, MUC1-8 and OVA8 to assess the effect of anchor modification on binding to H-2K b . RMSDs were calculated for the Ca backbone atoms and are listed in Table 3 . Superimposition of MUC1-8-5F8L with the molecular models, MUC1-8-5F and MUC1-8-8L, yielded RMSD values of 1Á18 Å and 0Á58 Å , respectively. For comparison, all peptides were also superimposed with the canonical OVA8 peptide, which yielded RMSD values of 0Á51 Å (MUC1-8), 0Á57 Å (MUC1-8-5F8L), 0Á60 Å (MUC1-8-8L) and 1Á27 Å (MUC1-8-5F) ( Fig. 3d-f) . The largest deviation Table 3 . Ca backbone atom RMSD (Å )   OVA8  MUC1-8  5F8L   OVA8  MUC1-8  0Á51  5F8L  0Á57  0Á19  5F  1Á27  1Á18  1Á14  8L 0Á60 0Á58 0Á55 Anchor modified residues in bold for peptide MUC1-8-5F8L (crystal structure), MUC1-8-5F and MUC1-8-8L (models).
was observed between the 5F anchor modified peptide (MUC1-8-5F) with RMSD values of 1Á27 Å (with OVA8), 1Á18 Å (with MUC1-8) and 1Á14 Å (with MUC1-8-5F8L). This data correlated well with the affinity measurements performed at 4° (Table 1) . Intermolecular H-bonds (summarized in Table 4 ).
Discussion
The selection of suitable antigens to elicit an effective immunological response in cancer patients is the first step to designing an effective vaccine. However, tolerance to these antigens remains an obstacle to overcome. Furthermore, identification of the antigenic portion and most importantly the immunogenic fragments remains challenging. To date, medium-to-high affinity peptides selected for cancer immunotherapy have resulted in only limited success in clinical trials. For example, partial or complete tumour regression was observed in only 10-30% of patients receiving melanoma peptides. 46 The efficacy of high-affinity 'self' epitope to induce an effective CTL response and provide protection and eradication of tumour cells has been unsuccessful because of the absence of T cells, which have been deleted during the development of the immune system. [2] [3] [4] [5] [6] More recently low-tomedium affinity peptides have been selected, which have yielded more promising results. 47 For example, high vaccination efficiency was observed for heteroclitic variants of low-affinity epitopes from the naturally expressed murine telomerase reverse transcriptase (mTERT) 47 and mice immunized with the low-affinity p572 and p988 epitopes resulted in protection against tumour challenge. 47 In addition, the recent identification and validation of seven low-affinity epitopes from known HLA-A2.1-restricted melanoma-associated antigens that do not conform to the canonical anchor motif for this HLA molecule were reported. Anchor modifications to these epitopes led to improved HLA binding and improved capacity to stimulate T cells. 48 Previously, we reported the crystal structure of the lowaffinity non-canonical MUC1-8 peptide in complex with H-2K b .
14 Furthermore, MUC1-8 was also shown to be capable of inducing immune responses in mice despite the low affinity for H-2K
b . Herein, we report the crystal structure of the MUC1-8-5F8L peptide in complex with H-2K b , which provides insight into the enhanced binding of the parent MUC1-8 peptide to H-2K b following modification of the non-canonical anchor residues to canonical ones (Thr P5 to Phe and Ala P8 to Leu), MUC1-8-5F8L. Enhanced T-cell responses were observed, which varied depending on which anchor was modified. The biological data revealed that modification of the central anchor P5 to Phe (MUC1-8-5F), increased peptide affinity (as measured by competition studies) by sevenfold compared to modification of the P8 residue to Leu (MUC1-8-8L) which only increased threefold compared to MUC1-8. In comparison, MUC1-8-5F8L showed a significant 14-fold increase in binding affinity. Similar results were also obtained for the stabilization studies using TAP2-deficient RMA-S cells as determined by FACScan.
T-cell responses in vivo also revealed that C57BL/6 mice immunized with the doubly substituted MUC1-8 peptide, MUC1-8-5F8L, recognized all other peptides (MUC1-8, MUC1-8-5F and MUC1-8-8L) more strongly. Although weaker T-cell responses were observed in MUC1 · HLA-A2 transgenic mice, the overall trend revealed that they are more immunogenic (tolerance could be overcome) with anchor substitutions to the non-canonical low-affinity MUC1-8 peptide. Enhanced immunogenicity and binding of non-immunogenic low affinity peptides to HLA-A2.1 has been achieved with a tyrosine substitution at the P1 position. Binding affinity can be increased 55-fold and/or stabilized for more than 2 hr compared to parent peptides. Most importantly, the variants could trigger CTL that also recognize the parent peptide. 49 Similarly, enhanced immune responses and binding to H-2K b were observed when the lowaffinity MUT1 peptide, a TAA isolated from 3LL Lewis lung carcinoma, was modified at the anchor positions P3, P5 and P8. 50 Furthermore, we have immunized mice with a higher affinity peptide (SAPDTRPA to SAPDT-GalNAc-RPA) where the affinity is similar to that for MUC1-8-5F8L. The T cells that are generated recognized the mutated higher affinity peptide more efficiently compared to the non-mutated, lower affinity peptide. 16 The crystal structure of MUC1-8-5F8L revealed that a number of H-bonds were lost at the N-terminus, namely P8 with Lys 146 (also observed for MUC1-8 with P8 residue Ala). The bound conformation of the MUC1-8-5F8L peptide was very similar to that of MUC1-8 mainchain and comparable to that of OVA8. Interestingly, the number of water molecules surrounding the MUC1-8-5F8L peptide was lower 6 than that for MUC1-8 10 and more comparable to that of OVA8 7 . The C and F pockets are fully occupied by the larger hydrophobic residues, Phe and Leu, and help to stabilize the peptide within the binding groove in a similar manner to OVA8, attributed to the strong binding affinity of this peptide for H-2K
b . The large cavities present at both the C and F pockets in the MUC1-8 structure are occupied with water molecules which help stabilize the low-affinity MUC1-8 peptide; these water molecules are absent in the high-affinity binding peptides MUC1-8-5F8L and OVA8. It is noteworthy, that compared to OVA8 and MUC1-8, there are no water molecules in the E pocket of H-2K b for the H-2K b -MUC1-8-5F8L crystal structure.
The molecular modelling studies suggested that MUC1-8-5F deviated by the greatest amount from the parent MUC1-8 peptide structure, OVA8 and MUC1-8-5F8L (Table 3) . RMSDs between MUC1-8-8L and MUC1-8, OVA8 and MUC1-8-5F8L were lower (Table 3) , suggesting that modifications in the C terminus of the peptide do not affect the peptide-H-2K b complex structure to the same extent; the data correlated well with the affinity data obtained at 4°.
Overall, this study validated the finding that anchor modifications made to non-canonical tumour epitopes, such as MUC1-8, can significantly enhance binding to the MHC class I molecule H-2K b and, in this case, also improve T-cell responses. The results are very encouraging and warrant continued efforts to identify low-affinity peptides that can subsequently be modified to yield analogues with high affinity for MHC and potent T-cell stimulatory activity.
